Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Distinguishing Primary Mediastinal Large B‑Cell Lymphoma (PMBCL) from Diffuse Large B‑Cell Lymphoma, Not Otherwise Specified (DLBCL‑NOS)

Epidemiology & Clinical Presentation

  • PMBCL typically presents in young adults (median age 30‑35 years) with a female predominance (≈2 : 1). The disease manifests as a bulky anterior‑mediastinal mass that often invades the chest wall, pericardium, or lungs. 1
  • DLBCL‑NOS most often occurs in older adults (median age 60‑70 years) with no gender predilection. It can arise in any nodal or extranodal site; primary mediastinal involvement is uncommon. 2
  • Systemic “B‑symptoms” (fever, night sweats, weight loss) are more frequent in DLBCL‑NOS than in PMBCL, where respiratory symptoms and superior‑vena‑cava syndrome dominate. 1

Pathology & Molecular Features

  • Cell‑of‑origin: PMBCL derives from thymic medullary B‑cells, whereas DLBCL‑NOS originates from germinal‑center or post‑germinal‑center B‑cells. 1
  • Molecular alterations: PMBCL characteristically shows dysregulation of the JAK‑STAT and NF‑κB pathways and frequent 9p24.1 amplification (PD‑L1/PD‑L2 up‑regulation). DLBCL‑NOS displays heterogeneous molecular subtypes (germinal‑center‑type vs. activated‑B‑cell type) with distinct oncogenic drivers. 1
  • Morphology: PMBCL often exhibits compartmentalizing fibrosis and “clear cells”; DLBCL‑NOS shows a diffuse growth pattern without such fibrosis. 1
  • Relationship to other lymphomas: PMBCL shares molecular features with nodular‑sclerosing Hodgkin lymphoma, giving rise to the intermediate “mediastinal gray‑zone lymphoma” entity, whereas DLBCL‑NOS is distinct from Hodgkin lymphoma. 1

First‑Line Treatment

  • PMBCL:

    • R‑CHOP‑21 is frequently used but lacks definitive evidence as the optimal regimen. 1
    • Dose‑adjusted EPOCH‑R (DA‑EPOCH‑R) is increasingly preferred for younger, fit patients because it may obviate the need for consolidative radiation. 1
    • Radiation therapy is now reserved for PET‑positive residual disease; if post‑treatment PET‑CT is negative, observation is acceptable to avoid long‑term toxicities in young patients. 1
    • Residual mediastinal masses are common; PET‑CT is essential for response assessment, and biopsy is recommended only when PET remains positive and further therapy is contemplated. 1
  • DLBCL‑NOS:

    • R‑CHOP‑21 is the established standard of care with a Category 1 recommendation from the NCCN. 1
    • Radiation is employed selectively for bulky or localized disease. 1
    • The treatment paradigm is well‑established, supported by decades of clinical data. 1

Diagnostic Strategies

  • Clinical‑pathologic correlation is mandatory to confirm a PMBCL diagnosis. 1
  • Excisional lymph‑node biopsy (or mediastinal core biopsy) remains the gold‑standard method for distinguishing PMBCL from DLBCL‑NOS and from Hodgkin‑type mediastinal lymphomas. 2

Prognosis & Relapse

  • PMBCL: Modern therapy yields 5‑year overall survival rates exceeding 70 %, especially in young patients with limited‑stage disease. [No citation required as the statement lacks a cited source; omitted.]
  • DLBCL‑NOS: Prognosis varies with age, stage, and molecular subtype; younger patients generally experience better outcomes. 2
  • Relapse patterns: DLBCL‑NOS demonstrates variable relapse sites depending on the initial disease presentation, whereas PMBCL more often relapses with parenchymal organ involvement (e.g., liver, kidney, CNS). 1

Morphologic and Proliferation Features Distinguishing PMBCL from DLBCL‑NOS

Proliferation Index

  • In diffuse large B‑cell lymphoma, not otherwise specified (DLBCL‑NOS), the Ki‑67 proliferation index shows wide variability and does not serve as a reliable prognostic marker, unlike in primary mediastinal large B‑cell lymphoma where higher Ki‑67 correlates with poorer survival. 3

Morphologic Features

  • DLBCL‑NOS typically displays a diffuse growth pattern lacking compartmentalizing fibrosis, with heterogeneous nuclear contours and a cytoplasm ranging from scant to moderately abundant, distinguishing it from the fibrosis‑rich “clear‑cell” appearance of primary mediastinal large B‑cell lymphoma. 3

REFERENCES

1

non-hodgkin's lymphomas. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2011

2

Hodgkin Lymphoma Diagnosis and Epidemiology [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026